List of Excipients in Branded Drug VASERETIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	VASERETIC	enalapril maleate and hydrochlorothiazide	0187-0146	FERRIC OXIDE RED
Bausch Health US LLC	VASERETIC	enalapril maleate and hydrochlorothiazide	0187-0146	LACTOSE
Bausch Health US LLC	VASERETIC	enalapril maleate and hydrochlorothiazide	0187-0146	MAGNESIUM STEARATE
Bausch Health US LLC	VASERETIC	enalapril maleate and hydrochlorothiazide	0187-0146	SODIUM BICARBONATE

VASERETIC Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

VASERETIC is a mature fixed-dose combination of enalapril maleate and hydrochlorothiazide. Its commercial value no longer depends on primary-compound exclusivity. The strongest opportunities are low-cost generic supply, excipient-led differentiation, improved adherence, global re-registration, and reformulation into patient-friendly dosage forms.

The product combines an angiotensin-converting enzyme inhibitor, enalapril, with a thiazide diuretic, hydrochlorothiazide. The legacy U.S. product has no meaningful composition-of-matter exclusivity remaining, and biosimilar pathways are irrelevant because VASERETIC is a synthetic small-molecule combination tablet.[1][2]

What is VASERETIC and which excipients does it contain?

VASERETIC contains enalapril maleate and hydrochlorothiazide in fixed-dose tablet strengths. The principal marketed strengths are 5 mg/12.5 mg and 10 mg/25 mg, although availability can vary by jurisdiction and manufacturer.[1]

VASERETIC active ingredients

Component	Function	Commercial relevance
Enalapril maleate	ACE inhibitor prodrug	Requires protection from moisture and control of dissolution
Hydrochlorothiazide	Thiazide diuretic	Low-dose, potent API with content-uniformity requirements
Lactose	Diluent and tablet bulk agent	Potential issue for lactose-intolerant patients and direct-compression optimization
Starch or pregelatinized starch	Binder, disintegrant, or filler	Supports manufacturability and tablet breakup
Sodium bicarbonate	Alkalinizing or stabilizing excipient	May influence microenvironmental pH and enalapril stability
Magnesium stearate	Lubricant	Excess levels can slow dissolution
Colorant, where applicable	Product identification	Enables strength differentiation and brand recognition

The exact inactive-ingredient profile should be taken from the applicable FDA label and current manufacturer filing because generic VASERETIC-equivalent products may use different excipient systems while maintaining pharmaceutical equivalence.[1][3]

What formulation problems must an excipient strategy solve?

The formulation must address four technical risks:

1. Enalapril degradation under moisture and unfavorable pH conditions.
2. Low-dose hydrochlorothiazide distribution and content uniformity.
3. Lubricant-related dissolution changes, particularly from excessive magnesium stearate.
4. Tablet differentiation between strengths without creating unnecessary coating or manufacturing cost.

Enalapril maleate is generally more formulation-sensitive than hydrochlorothiazide. A formulation developer should prioritize moisture control, blend uniformity, compression robustness, and dissolution equivalence over cosmetic differentiation.

What excipient system is most suitable for a generic VASERETIC tablet?

A conventional immediate-release matrix remains the lowest-risk approach. The preferred platform is a low-moisture, direct-compression or dry-granulated tablet with a rapidly disintegrating filler-binder system.

Recommended excipient architecture

Formulation objective	Preferred excipient approach	Reason
Improve flow	Microcrystalline cellulose or co-processed filler	Supports uniform dosing of low-dose hydrochlorothiazide
Improve compactability	Microcrystalline cellulose, spray-dried lactose, or mannitol	Reduces capping and tablet-strength variability
Support disintegration	Crospovidone, croscarmellose sodium, or low-level starch	Preserves immediate-release performance
Control moisture	Low-moisture excipients and high-barrier packaging	Limits enalapril degradation
Maintain dissolution	Low-level magnesium stearate with controlled mixing time	Avoids hydrophobic over-lubrication
Control pH	Sodium bicarbonate or another justified alkalinizing system	Can support enalapril stability, subject to compatibility data
Improve patient acceptability	Film coating with low-moisture polymer system	Masks taste and supports strength identification

The lowest regulatory-risk generic should remain compositionally simple. Introducing a novel stabilizer, complex coating system, or modified-release mechanism increases development burden without necessarily creating pricing power.

Should lactose be retained?

Lactose is commercially attractive because it is inexpensive, well understood, and widely accepted by regulators. Replacing it can create a differentiated product for patients who avoid lactose, but the commercial segment is limited because the lactose quantity in a tablet is generally small.

A lactose-free platform may still be valuable when it also improves flow, compressibility, moisture performance, or supply resilience. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and selected co-processed excipients are potential alternatives. The replacement should be justified by manufacturability or market access rather than lactose avoidance alone.

What patents protect VASERETIC?

No commercially relevant primary patent barrier remains for the enalapril/hydrochlorothiazide combination in the United States. VASERETIC was introduced decades ago, and the relevant composition and product exclusivities expired long before the current generic market.[1][2]

Patent and exclusivity position

IP category	VASERETIC position	Strategic implication
Enalapril composition patent	Expired	No blocking compound patent
Hydrochlorothiazide composition patent	Expired	No blocking compound patent
Fixed-dose combination patent	Expired or commercially irrelevant	ANDA competition is feasible
Legacy formulation patents	Expired or nonblocking	Limited value for market defense
Method-of-use patents	No material current barrier expected	Hypertension indication is mature
Biosimilar exclusivity	Not applicable	Small-molecule generic pathway applies
Orange Book-listed blocking patents	No material live barrier expected	Product development can focus on equivalence and cost

The relevant regulatory route for a conventional equivalent is an abbreviated new drug application. A differentiated formulation could require a 505(b)(2) application if it cannot demonstrate the level of sameness required for an ANDA.[2][3]

When does VASERETIC lose exclusivity?

VASERETIC lost practical market exclusivity years ago. Its current commercial exposure is driven by generic substitution, reimbursement, supply reliability, and retail distribution rather than patent expiration timing.

Regulatory exclusivity and generic entry

A conventional generic sponsor does not need to wait for a future VASERETIC patent expiration if no blocking patent or regulatory exclusivity remains. Generic entry depends on:

• Demonstrating pharmaceutical equivalence.
• Meeting bioequivalence requirements.
• Addressing any applicable Paragraph IV or Paragraph III certification.
• Satisfying current manufacturing and quality standards.
• Obtaining approval for the specific strength and dosage form.

Paragraph IV litigation is unlikely to be the central risk for a product of this age. The larger risk is commercial crowding after approval.

What FDA regulatory strategy applies to VASERETIC?

ANDA strategy for an immediate-release tablet

An ANDA is the most efficient pathway for a conventional VASERETIC-equivalent product. The development program should include:

• Same active ingredients, strengths, dosage form, and route.
• Pharmaceutical equivalence.
• Comparative dissolution testing.
• Bioequivalence evidence where required.
• Stability data in the proposed container-closure system.
• Manufacturing-process validation.
• Impurity and degradation-product control.
• Labeling that conforms to the reference product.

The sponsor should avoid unnecessary excipient innovation if the objective is rapid approval and low cost. Excipient changes are permissible, but the finished product must remain equivalent and the inactive ingredients must comply with applicable FDA requirements.[2][3]

505(b)(2) strategy for differentiated products

A 505(b)(2) route becomes relevant for products such as:

• Orally disintegrating tablets.
• Sprinkle granules.
• Solubilized or taste-masked liquid formulations.
• Novel dose strengths.
• Multiparticulate products.
• Packaging systems with a validated stability advantage.
• Fixed-dose combinations with a materially different dosing profile.

This route can support a stronger commercial proposition but may require additional clinical, pharmacokinetic, or bridging evidence. A reformulation should have a clear reimbursement or adherence benefit before pursuing the higher development cost.

What formulations are protected or commercially differentiated?

The legacy immediate-release tablet is not a strong differentiation platform. Commercial opportunity is greater in formulations that solve a practical use problem.

Orally disintegrating tablet

An orally disintegrating tablet could target:

• Older adults with dysphagia.
• Patients with reduced dexterity.
• Home-care populations.
• Patients who have difficulty swallowing multiple tablets.

Crospovidone, croscarmellose sodium, mannitol, and low-moisture sweetening or flavor systems are potential excipient tools. The principal technical challenge is maintaining chemical stability while achieving rapid disintegration and acceptable taste.

Sprinkle or sachet formulation

A multiparticulate or sprinkle product could support patients unable to swallow tablets. Hydrochlorothiazide bitterness and enalapril taste must be controlled. Taste masking can use polymer coatings, ion-exchange systems, or lipid-based barriers, but these approaches increase manufacturing complexity and may affect dissolution.

Liquid formulation

A liquid product could address institutional or pediatric use, although the adult hypertension market provides limited pediatric volume. The main formulation risks are hydrolysis, pH-dependent stability, dose uniformity, preservative compatibility, and packaging interactions.

Modified-release formulation

Modified release is not an obvious fit for VASERETIC. Enalapril and hydrochlorothiazide are established immediate-release therapies, and a prolonged-release product would require a stronger clinical rationale. The development cost and regulatory burden would be difficult to justify without a demonstrable adherence or tolerability benefit.

How strong is the VASERETIC patent estate?

The patent estate is weak as a defensive asset and potentially useful only as a historical source of formulation and manufacturing knowledge. The commercial moat must come from execution.

Patent strength assessment

Dimension	Assessment	Explanation
Composition of matter	Very weak	Core APIs are long-established
Fixed-dose combination	Very weak	Mature combination with generic competition
Immediate-release formulation	Weak	Conventional dosage form and excipient options
Novel excipient platform	Moderate if newly developed	Protection depends on claim scope and enforceability
ODT or sprinkle formulation	Moderate	Potential for formulation and use claims
Manufacturing process	Moderate	Process patents may protect specific methods but are difficult to enforce broadly
Packaging and stability system	Limited to moderate	Can support narrow claims and commercial differentiation
Regulatory exclusivity	None expected to provide meaningful protection	Product age removes most exclusivity value

A new sponsor could file patents on a specific low-moisture formulation, particle-engineering method, taste-masking approach, or dosage form. Those patents would protect the new product, not restore exclusivity to the legacy VASERETIC formulation.

What commercial opportunities exist for VASERETIC?

Low-cost generic supply

The largest opportunity is a reliable, low-cost generic. Enalapril/hydrochlorothiazide is a standard antihypertensive combination, and procurement customers value:

• Consistent supply.
• Multiple strengths.
• Competitive unit pricing.
• Broad wholesaler coverage.
• Clean inspection history.
• Stable tablet quality.

A manufacturer with integrated API supply and efficient tableting can compete even in a crowded market.

Hospital and government tenders

The product may fit public-health and institutional procurement programs where fixed-dose combinations reduce pill burden. Tender success depends less on formulation novelty and more on:

• Price.
• Capacity.
• Registration status.
• Local manufacturing requirements.
• Packaging compliance.
• Delivery performance.

Emerging-market registration

Geographic expansion can provide better margins than the highly competitive U.S. generic market. Priority markets include countries where:

• Enalapril and hydrochlorothiazide remain guideline-supported.
• Fixed-dose combinations are reimbursed.
• Local generic competition is fragmented.
• Combination-pill adherence is a policy objective.
• The originator brand has limited current presence.

The registration strategy should use a modular dossier with country-specific labeling, stability data, packaging, and bioequivalence requirements.

Adherence-focused reformulation

A smaller but potentially higher-margin opportunity is a patient-centric dosage form. The best targets are ODT, easy-open packaging, and strength-color differentiation rather than complex modified release.

A product positioned around reduced pill burden may compete with separate enalapril and hydrochlorothiazide prescriptions. The sponsor should quantify whether the combination produces pharmacy or payer savings and whether the product is preferred over newer fixed-dose antihypertensive combinations.

Which companies are challenging VASERETIC?

VASERETIC competes primarily with generic manufacturers of enalapril/hydrochlorothiazide and with alternative fixed-dose antihypertensive combinations. The competitive set includes:

• Generic tablet manufacturers.
• Private-label pharmaceutical suppliers.
• Regional manufacturers in emerging markets.
• Producers of lisinopril/hydrochlorothiazide.
• Producers of losartan/hydrochlorothiazide.
• Producers of valsartan/hydrochlorothiazide.
• Producers of benazepril/hydrochlorothiazide.

The main competitive threat is therapeutic substitution, not patent litigation. Physicians and payers can select another ACE inhibitor/thiazide or an angiotensin-receptor blocker/thiazide combination based on price, formulary status, tolerability, and supply.

What generic launch risks exist for VASERETIC?

Technical risks

• Enalapril degradation during accelerated stability testing.
• Failure to match dissolution across pH conditions.
• Hydrochlorothiazide content-uniformity failures.
• Excessive tablet hardness or slow disintegration.
• Magnesium stearate over-lubrication.
• Moisture ingress through the package.
• Color or imprint differences that create medication-error concerns.

Commercial risks

• Rapid price erosion after multiple approvals.
• Low prescription volume relative to newer combinations.
• Wholesaler substitution toward higher-volume products.
• Difficulty obtaining preferred formulary placement.
• Tender dependence in institutional markets.
• API and packaging cost inflation.

Regulatory risks

• Incomplete reference-product characterization.
• Inactive-ingredient incompatibility.
• Insufficient stability data for the proposed packaging.
• Failure to address nitrosamine or other emerging impurity expectations where applicable.
• Manufacturing-site compliance findings.

How does VASERETIC compare with competing fixed-dose combinations?

Product	Combination	Market position	Commercial implication
VASERETIC	Enalapril plus hydrochlorothiazide	Mature ACE inhibitor/thiazide	Low-cost generic and adherence opportunity
ZESTRIL-HCT	Lisinopril plus hydrochlorothiazide	Broad generic familiarity	Strong substitution pressure
HYZAAR	Losartan plus hydrochlorothiazide	ARB/thiazide reference product	May be preferred for ACE-inhibitor intolerance
DIOVAN HCT	Valsartan plus hydrochlorothiazide	ARB/thiazide alternative	Competes in branded and generic channels
LOTENSIN HCT	Benazepril plus hydrochlorothiazide	Smaller ACE inhibitor segment	Less direct but relevant substitution

VASERETIC can compete on price and supply, but it has limited basis for premium pricing without a differentiated dosage form, packaging advantage, or market-specific regulatory positioning.

What licensing deals and manufacturing barriers matter?

There is limited licensing value in the legacy VASERETIC brand itself because the active ingredients and conventional formulation are mature. Licensing opportunities are more credible in:

• Enalapril or hydrochlorothiazide API supply.
• Co-processed excipient technology.
• ODT manufacturing.
• Taste-masking platforms.
• High-barrier blister packaging.
• Regional distribution and registration rights.
• Contract manufacturing capacity.

Manufacturing barriers are manageable but not trivial. The sponsor needs validated control of low-dose blend uniformity, moisture, compression, coating, packaging, and stability. An integrated manufacturer with established cardiovascular-product capacity may have a cost advantage over a company entering the category solely for one product.

Key Takeaways

• VASERETIC is an old fixed-dose combination of enalapril maleate and hydrochlorothiazide.
• No meaningful primary patent or biosimilar barrier is expected to limit conventional generic entry.
• The lowest-risk product is an immediate-release tablet using a moisture-controlled, rapidly disintegrating excipient system.
• Lactose-free, ODT, sprinkle, and easy-open-packaging strategies offer the clearest differentiation.
• Modified release has weak commercial justification unless supported by a specific adherence or pharmacokinetic benefit.
• Generic competition and therapeutic substitution are greater risks than Paragraph IV litigation.
• The strongest near-term opportunities are reliable supply, institutional tenders, emerging-market registration, and low-cost manufacturing.
• New patent value would come from a differentiated formulation, process, packaging system, or delivery technology, not from the legacy VASERETIC composition.

FAQs

Is VASERETIC still patent protected?

No material patent protection is expected to block conventional generic development. The product and its active ingredients have been commercially established for decades.

Can VASERETIC be reformulated as an orally disintegrating tablet?

Yes. An ODT could use mannitol, crospovidone, croscarmellose sodium, and moisture-protective packaging, but taste masking and enalapril stability would require focused development.

Is VASERETIC a biologic subject to biosimilar competition?

No. VASERETIC is a synthetic small-molecule combination and is regulated through generic-drug pathways rather than biosimilar pathways.

What is the best excipient replacement for lactose in VASERETIC?

Mannitol or microcrystalline cellulose is a practical starting point, depending on the desired balance of flow, compactability, tablet size, moisture performance, and disintegration.

Does a new VASERETIC formulation create new patent value?

Potentially. A narrowly defined formulation, taste-masking system, manufacturing process, or packaging technology may support new patent claims if it provides a novel and non-obvious technical result.

References

1. U.S. Food and Drug Administration. (n.d.). VASERETIC- enalapril maleate and hydrochlorothiazide tablet: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format guidance for industry.
4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.